MP Healthcare Venture Management

Type

Venture Capital

Status

Active

Location

Cambridge, United States

Total investments

41

Average round size

20M

Portfolio companies

23

Rounds per year

2.28

Lead investments

2

Follow on index

0.44

Exits

8

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2006 was created MP Healthcare Venture Management, which is appeared as VC. The leading representative office of defined VC is situated in the Boston. The venture was found in North America in United States.

We also calculated 1 valuable employee in our database.

The fund has no exact preference in a number of founders of portfolio startups. If startup sums 2 or 4 of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Thrasos, Genkyotex, Covagen For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the MP Healthcare Venture Management, startups are often financed by Atlas Venture, SR One, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are SR One, M Ventures, Atlas Venture. In the next rounds fund is usually obtained by SR One, Andera Partners, Ventech.

The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2014. The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 16 percentage points less often commits exit comparing to other organizations. This MP Healthcare Venture Management works on 0 percentage points less the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcareMedtech
Stage focus
Series ASeedSeries BSeries C
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 39 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
41
Lead investments
2
Exits
8
Rounds per year
2.28
Follow on index
0.44
Investments by industry
  • Biotechnology (38)
  • Health Care (20)
  • Therapeutics (16)
  • Pharmaceutical (11)
  • Biopharma (8)
  • Show 7 more
Investments by region
  • United States (19)
  • Switzerland (5)
  • Canada (3)
  • United Kingdom (6)
  • Germany (1)
  • Show 4 more
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
25M
Group Appearance index
0.90
Avg. company exit year
8
Avg. multiplicator
2.16
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Fanbot 14 Jul 2017 Retail, Food and Beverage, Marketing Automation, Restaurants, Loyalty Programs Seed 250K Jalisco, Guadalajara, Mexico
Genkyotex 09 Jul 2012 Biotechnology, Health Care, Pharmaceutical Late Stage Venture 27M Switzerland, Geneva, Geneva
Outrun TX 18 Apr 2024 Health Care, Medical, Therapeutics Seed 10M Dundee, Dundee City, United Kingdom

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.